People on the move
appointments in the pharmaceutical development and manufacturing
arena, headed this week by senior appointments at world number one
drugmaker Pfizer.
Pete Stevenson has been appointed vice president of Pfizer Global Manufacturing (PGM), with responsibility for contract manufacturing, procurement and Pfizer CentreSource. He will report to Nat Ricciardi, PGM's president. In addition, Michael Kosko has been appointed president of Pfizer CentreSource (PCS), a provider of active pharmaceutical ingredients (APIs), fine chemical intermediates and finished dosage forms to the pharmaceutical industry. Kosko will report to Stevenson.
Phase Bioscience, a specialist in recombinant production technologies, has appointed Gabriel Cipau as chief executive and chairman, as well as Cindy Clark as president and chief business officer.
Peter Glynn-Jones, non-executive chairman of UK encapsulation specialist BioProgress, has died suddenly at the age of 58. He joined the board of BioProgress in 2003 and was formerly a senior executive of SmithKline Beecham, now GlaxoSmithKline, and a non-executive director of Peter Black. An announcement in relation to a successor will be made in due course, said the firm.
France's NicOx has appointed Dr Ali Raza as head of research and development, reporting to chief executive Michele Garufi. Dr Raza will be responsible for the research, drug development and clinical development departments. His most recent position was as head of clinical development and regulatory affairs at UK biopharma company Renovo.
Shire Pharmaceuticals of the UK's US unit in Philadelphia has appointed Michael Cola as executive vice president of global therapeutic area business units. Cola formerly worked as head of product development at AstraMerck/AstraZeneca and most recently served as president of life sciences at Safeguard Scientifics. He will join Shire's Executive Committee and report directly to CEO Matt Emmens.
Dr Matthew Gaunt of the University of Cambridge in the UK delivered the Dowpharma Prize Lecture at Chiral Europe, 10-11 May. Dr Gaunt's paper, entitled 'New Catalytic Technology for Chemical Synthesis', was selected from among 15 abstracts.
Martin Flower, deputy chairman of the Severn Trent water company, has been appointed non-executive director of Croda effective immediately, and new chairman effective the end of September. Flower will replace Antony Beevor, who is retiring.
Drug delivery firm Enzon Pharmaceuticals has promoted Craig Tooman to the post of chief financial officer, filling a slot vacated by Kenneth Zuerblis in April. Tooman most recently served as Enzon's executive vice president of strategic planning and corporate communications. Zuerblis resigned as the company's CFO in mid-April for personal reasons.
